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Peritoneal carcinomatosis (PC) is a rare disease defined as diffused implantation
of neoplastic cells in the peritoneal cavity. This clinical picture occurs during the
evolution of peritoneal tumors, and it is the main cause of morbidity and mortality
of patients affected by these pathologies, though cytoreductive surgery with heated
intra-peritoneal chemotherapy (CRS/HIPEC) is yielding promising results. In the
present study, we evaluated whether the tumor microenvironment of low-grade and
high-grade PC could affect the phenotypic and functional features and thus the
anti-tumor potential of NK cells. We show that while in the peritoneal fluid (PF)
of low-grade PC most CD56dim NK cells show a relatively immature phenotype
(NKG2A+KIR–CD57–CD16dim), in the PF of high-grade PC NK cells are, in large
majority, mature (CD56dimKIR+CD57+CD16bright). Furthermore, in low-grade PC,
PF-NK cells are characterized by a sharp down-regulation of some activating receptors,
primarily NKp30 and DNAM-1, while, in high-grade PC, PF-NK cells display a higher
expression of the PD-1 inhibitory checkpoint. The compromised phenotype observed
in low-grade PC patients corresponds to a functional impairment. On the other hand,
in the high-grade PC patients PF-NK cells show much more important defects that
only partially reflect the compromised phenotype detected. These data suggest that
the PC microenvironment may contribute to tumor escape from immune surveillance
by inducing different NK cell impaired features leading to altered anti-tumor activity.
Notably, after CRS/HIPEC treatment, the altered NK cell phenotype of a patient
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with a low-grade disease and favorable prognosis was reverted to a normal one. Our
present data offer a clue for the development of new immunotherapeutic strategies
capable of restoring the NK-mediated anti-tumor responses in association with the
CRS/HIPEC treatment to increase the effectiveness of the current therapy.
Keywords: human NK cells, peritoneal carcinomatosis, pseudomyxoma peritonei, NK cell receptors, immune
escape, immune checkpoint, PD-1/PD-L, NKp30
INTRODUCTION
Peritoneal carcinomatosis (PC) is a histologically heterogeneous,
progressive malignant extremely rare disease. It is characterized
by the accumulation of tumor tissue in the peritoneal cavity
that ranges in biologic behavior from benign to highly
malignant (1–4).
Low-grade peritoneal diseases include well-differentiated
papillary mesothelioma, a rare subtype of epithelioid
mesothelioma, arising from the mesothelial layers of the
peritoneum and pseudomyxoma peritonei, a mucinous
adenocarcinoma of the appendix spread to the peritoneal
cavity which is characterized by recurrent voluminous mucinous
ascites (4). These tumors grow along the peritoneal surfaces
(feature that makes them susceptible to surgical debulking) (1).
Although frequently characterized by an indolent course, they
are not a harmless condition, and are fatal if untreated. A second
category of peritoneal diseases includes peritoneal mesothelioma,
an aggressive malignancy arising from mesothelial cells within
the serosal lining of the peritoneum, and peritoneal mucinous
carcinomatosis, an invasive, high-grade, poorly differentiated
carcinoma with large extracellular pools of mucin. This
second type originates from mucinous carcinomas of the
gastrointestinal tract (5), gallbladder (6), pancreas, or ovary (7),
thus representing the metastatic spread of a primary cancer
resulting in peritoneal carcinomatosis. Similar to high-grade
peritoneal mesotheliomas, it is always associated with poor
patients survival.
In view of the poor efficacy of classical therapies, alternative
treatments have increasingly been applied, including the
cytoreductive surgery (CRS) associated with intraoperative
intraperitoneal chemohyperthermia (HIPEC) (1, 8, 9). In general,
in low-grade histologic variants this treatment gives excellent
long-lasting results, while responses in high-grade peritoneal
mucinous carcinomatosis are limited. Currently, there is no
marker that allows to predict which patients may benefit
from these aggressive treatments. Moreover, the cellular and
molecular mechanisms responsible for the proliferative potential
and the resistance to therapy by peritoneal carcinomatosis tumor
cells have not been elucidated. In this context, however, it
became clear that immunological alterations occurring in the
tumor microenvironment seem to favor tumor growth and
implantation, thus resulting in a poorer prognosis. Indeed,
PC tumor cells can develop different mechanisms of immune
escape capable of suppressing the activity of the immune system,
including induction of PD-1 expression on T cells and release
of pro-tumoral/immunosuppressive cytokines (such as IL6, IL10,
and TGF-beta1) that may either regulate tumor growth ormodify
the anti-tumor immune responses (10–12).
Natural Killer (NK) cells play a fundamental role in the
immune response against tumor cells (13, 14). For this reason,
immunotherapies exploiting anti-tumor NK cell activity are the
most promising in the treatment of so far incurable tumors
(15–20). NK cell functions (21), including potent anti-tumor
cytolytic activity, cytokine production, and cross-talk with
different immune cells (22), are controlled by a balance of
several inhibitory and activating receptors (13, 23). In humans,
the inhibitory receptors include HLA-I-specific and non-HLA-
I specific receptors. The HLA-I-specific inhibitory receptors
are represented by the well-known killer immunoglobulin-like
receptors (KIR) that recognize the polymorphic HLA-A, -B,
and -C molecules, the immunoglobulin-like receptor 1 (LIR-
1/ILT-2) that is specific for different HLA-class I molecules,
and the CD94/NKG2A heterodimer that recognizes HLA-E,
a non-polymorphic non-classical HLA molecule (24–26). The
non-HLA-I-specific inhibitory receptors include the immune
checkpoint PD-1 that was originally described on T cells (27),
but recently shown also on a subset of peripheral blood (PB) NK
cells from healthy HCMV+ individuals and in tumor patients
(28–30). The PD-1+ NK cell subset is mainly composed of fully
mature cells, expressing the CD56dimKIR+LIR−1+NKG2A–
CD57+CD16bright surface phenotype (29). Themain non-HLA-
I-specific activating NK receptors are NKp46, NKp30, NKp44
(called “natural cytotoxicity receptors,” NCR), NKG2D, and
DNAM-1 (31, 32). Many of the activating NK receptor ligands
have been identified and shown to be variably expressed by
tumors (14).
Given the importance of NK cells in anti-tumor responses, it
is not surprising that tumors use a wide range of mechanisms
to avoid recognition by NK cells (33). Many mechanisms
have been described, such as expression of tumor ligands
for inhibitory receptors, induction/up-regulation of inhibitory
receptors expression by NK cells, release of soluble ligands
for activating NK receptors, downregulation of activating
receptors on NK cells (19, 28, 34–36), and release of pro-
tumoral/immunosuppressive soluble factors. These mechanisms
lead to a suppression of anti-tumor NK cell activity and to an
uncontrolled tumor growth.
In the present study, we analyzed PB and peritoneal fluid
(PF)/ascites derived NK cells in patients with low-grade or high-
grade PC and the ability of the PC tumor microenvironment to
shape the NK cell compartment. We show that both low-grade
and high-grade PC patients show an impaired NK cell phenotype,
but with defects of different nature (e.g., downregulation of the
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main activating NK cell receptors vs. up-regulation/induction
of inhibitory receptors such as PD-1). In addition, we observed
different functional impairments in low-grade and high-grade PC
patients. This analysis indicates that, based on the tumor grade,
PC microenvironment may differently contribute to the tumor
escape from immune surveillance.
Notably, after CRS/HIPEC treatment, the altered NK cell
phenotype of a patient with a low-grade disease and favorable
prognosis was reverted to a normal one (37).
Although in this study we examined a small group of patients,
especially because of the rarity of this disease, our observations
represent an important basis to carry on further investigations
and to better understand the mechanisms underlying the
development of PC and the possible intervention increasing the
effectiveness of the CRS/HIPEC treatment by restoring also the
NK-mediated anti-tumor responses.
METHODS
Patients and Samples
This study included 8 patients with peritoneal carcinomatosis
(PC) who had tumor surgery on PC between 2015 and 2018:
– 2 patients with well-differentiated papillary mesothelioma of
the peritoneum (Pt. 6, Pt. 7)
– 3 patients with low-grade pseudomyxoma peritonei (Pt. 1, Pt.
8, Pt. 9)
– 2 patients with mucinous peritoneal carcinoma arising from
epithelial ovarian cancer (Pt. 2, Pt. 3)
– 1 patient with mucinous PC arising from colorectal cancer
(Pt. 4)
Samples of PB and PF/ascites from all the patients were collected
before CRS/HIPEC treatment (time 0) and, when possible, at
different time points after treatment (time 1: 48 h, time 2: 7
days) and analyzed without further processing or culturing with
the exception of primary cell lines and functional experiments
(see below).
Mononuclear cells from heparinized PB and from PF were
obtained by density gradient centrifugation over Ficoll (Sigma,
St. Louis, MO), and then resuspended in RPMI 1640 medium,
supplemented with 2mM glutamine, 50µg/mL penicillin,
50µg/mL streptomycin, and 10% heat-inactivated FCS (Fetal
Calf Serum, Biochrom Ltd). Buffy-coats (healthy controls) were
collected from volunteer blood donors admitted at the blood
transfusion center of IRCCS Ospedale Policlinico San Martino,
Genova, Italy.
In some cases, we obtained primary cell lines by culturing PF
free cells for 2 weeks in the presence of PF derived from the
matched patients.
Ethical Statements
This study was carried out in accordance with the
recommendations of the ethical standards of the institutional
and/or national research committee. The protocol was approved
by the ethics committee of the Liguria Region, Genova, Italy (no.
428Reg2014 for PC patients and no. 39/2012 for healthy donors).
All subjects gave written informed consent in accordance with
the Declaration of Helsinki.
Monoclonal Antibodies
The following mAbs generated in the Laboratory of Molecular
Immunology, DIMES, University of Genoa were used in
this study:
A6/136 (IgM, anti-HLA-1); L14 (IgG2A, anti-Nectin-2);
5A10 (IgG1, anti-PVR); 11PB6 (IgG1, anti- KIR2DL1/S1);
GL183 (IgG1, anti-KIR2DL2/L3/S2); AZ158 (IGg2A, anti-
KIR3DL1/S1/L2); C227 (IgG1, anti-CD69); BAB281 (IgG1, anti-
NKp46); AZ20 (IgG1, anti-NKp30); QA79 (IgG1, anti-p75); F278
(IgG1 anti-LIR1); ECM217 (IgG2b, anti-NKG2D); GN18 (IgG3,
anti-DNAM-1); PP97 (IgM, anti-CD45).
The following purchased mAbs were used in this study: anti-
ULBP1 (clone M295), anti-ULBP2 (clone M310), anti-ULBP3
(clone M550) (Amgen, Seattle, WA); anti-CXCR4-APC (R&D
Systems, MN, USA); anti-ESA, IgG1 (Novocastra Laboratories
Ltd.); anti-CD90, IgG1 (BD Biosciences, Pharmingen, CA,
USA); anti-CD16-PerCP5.5 (clone 3G8) (BD Biosciences,
Pharmingen, CA, USA); anti-CD107-PE (clone H4A3) (BD
Biosciences, Pharmingen, CA, USA); anti-NKG2A-APC (clone
Z199) (Beckman Coulter/Immunotech, Marseille, France); anti-
PD-1 PE (clone 1.3.1.3) (Miltenyi Biotec, Bergisch Gladbach,
Germany); anti-CD57-Vioblue (Miltenyi Biotec, Bergisch
Gladbach, Germany); anti-B7-H6 (clone MAB7144) (R&D
Systems, MN, USA); anti-PD-L1 (clone 27A2) (MBL, Woburn,
MA); anti-PD-L2 (clone 176611) (R&D Systems, MN, USA);
anti-CK7 (clone OV-TL 12/30) (Abcam, Cambridge, Regno
Unito); anti-MUC2 (clone Ccp58) (Abcam, Cambridge,
Regno Unito); anti-CD56-PC7 (clone c218) (Beckman
Coulter/Immunotech, Marseille, France); anti-CD3-Viogreen
(BW264/56 clone), anti-CD19-VioGreen (LT20 clone), anti-
CD14-Viogreen (TÜK4 clone) (Miltenyi Biotec, Bergisch
Gladbach, Germany).
Flow Cytometer Analysis
Analyses were performed using a FACSCalibur or a FACSVerse
flow cytometer (BD) and data were analyzed using the
CellQuestPro software or the FacsSuite software, respectively
(Becton Dickinson, Mountain View, CA). We also used
FlowJo v10 for visualization of the unbiased t-distributed
stochastic neighbor-embedding (t-SNE) algorithm. Analysis
of NK cells was made on CD56dimCD3-CD19-CD16+/–
gated cells. For KIR analysis, we used a pool of anti-
KIR2DL1/S1, anti-KIR2DL2/L3/S2, and anti-KIR3DL1/S1/L2
mAbs. For analysis of CD45neg primary cell lines derived
from PF cells, we analyzed the surface expression of different
markers (including CD90, ESA, CK7, MUC2) and a series of
ligands for NK cell receptors (including HLA-I, PVR, Nectin-
2, B7-H6, ULBPs, PD-L1, and PD-L2 molecules) (38). In
degranulation experiments, performed with frozen cells, the
7AAD (BD Biosciences, Pharmingen, CA, USA) nucleic acid
dye was used for the exclusion of non-viable cells in flow
cytofluorimetric assays.
Cytokine Production
To analyze the presence of a panel of different soluble factors,
we used two different kits (Bio-Plex Pro Human Cytokine 48-
plex Assay, Bio-Plex Pro Human TGF-beta1 and TGF-beta2
Assay from Bio-Rad) (Hercules, CA, USA) and all assays were
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FIGURE 1 | Surface phenotype of CD56dim NK cells derived from peripheral blood or peritoneal fluid of patients affected by PC. Cytofluorimetric analysis of the
expression of different cell surface markers on CD56dim-gated NK cells from peripheral blood of healthy donors (HD-NK) ( bars), peripheral blood of PC patients
(PB-NK) ( bars) (n = 8: Pt. 1, Pt. 2, Pt. 3, Pt. 4, Pt. 6, Pt. 7, Pt. 8, Pt. 9) and peritoneal fluid of PC patients (PF-NK) ( bars) (n = 6: Pt. 1, Pt. 2, Pt. 3, Pt. 4, Pt. 6, Pt.
8). Histograms indicate the percent ±SD of HD-/PB-/PF-NK cells positive for the indicated receptors. In order to compare the expression of the three groups
simultaneously (i.e., HD-NK, PB-NK, and PF-NK), we computed the Krustall rank sum tests for each cell surface marker analyzed. *P < 0.05.
performed by Bioclarma s.r.l. (Torino, Italy) according to Biorad
kit procedures. Soluble B7-H6 (sB7-H6) was measured in cell
supernatants by enzyme-linked immunosorbent assay (Human
B7-H6 DuoSet ELISA, R&D Systems, MN, USA).
Cell Line and Degranulation Assays
The target cell line used in this study was the human
erythroleukemia K562 cell line.
For degranulation assay, PB and PF lymphocytes were
cultured O.N. in the presence of sub-doses of IL15 (0.5 ng/ml)
and then co-incubated with K562 target cells at an E/T ratio of 1:4
in a final volume of 200 µl in round-bottomed 96-well plates at
37◦C and 5% CO2 for 3 h in culture medium supplemented with
anti-CD107a-PE mAb. Surface staining was done by incubating
the cells with anti-CD3, anti-CD56 anti-CD19, and anti-CD16
for 30min at 4◦C. The cells were washed and analyzed by flow
cytometry (FACSVerse, Becton Dickinson). Analysis of NK cells
was made on CD56+ CD3− CD19− gated cells.
Statistical Analysis
The unsupervised hierarchical clustering was performed by using
the online tool MORPHEUS (https://software.broadinstitute.
org/morpheus/).
In order to compare the expression of the three groups
simultaneously (i.e., HD-NK, PB-NK, and PF-NK), we computed
the Krustall rank sum tests for each cell surface marker analyzed.
These analyses were performed using R
software (Figures 1, 2).
In order to compare the expressions of low-grade and high-
grade PF-NK, we performed the Power Analysis for Two-group
Independent sample t-test, using the R package pwr. In this test
“d” represents the Cohen’s d that is an effect size used to indicate
the standardized difference between two means. Cohen’s d equal
to 0.2, or to 0.5, or to 0.8 were considered a small, medium and
large effect size. Each test was considered valid if the significance
level was ≤ 0.05 and if the power was ≥ 0.80 (Figure 3).
RESULTS
Phenotypic Analysis of Peripheral Blood
and Peritoneal Fluid/Ascites NK Cells From
Patients Affected by Peritoneal
Carcinomatosis
To analyze the impact of the PC tumor microenvironment on
NK cells, we characterized fresh NK cells derived from the
peripheral blood (hereafter termed as PB-NK) and from the
peritoneal fluid/ascites (hereafter termed as PF-NK) of patients
affected by low-grade and high-grade PC by flow cytometry for
the expression of a large panel of cell surface markers. The results
were compared with those obtained using NK cells derived from
peripheral blood of healthy donors (hereafter termed HD-NK).
CD56bright NK cell subset on PF-NK cells showed phenotypic
features similar to those of classical CD56bright PB-NK cells
although the proportion of this subset was higher in the PF
compartment (PF average score: 39%; PB average score: 9%). On
the other hand, CD56dim PB-, and PF-NK cells derived from the
same patients and HD-NK cells showed some differences in the
expression of both activating and inhibitory NK cell receptors.
In particular, CD56dim PF-NK cells displayed lower levels of
KIR and CD57 (a marker typical of terminally differentiated NK
cells) and higher level of PD-1 as compared to CD56dim HD-
and PB-NK cells (Figure 1). Interestingly, most CD56dim PF-
NK cells displayed a significant down-regulation of CD16, the
Fc-gamma receptor responsible for antibody-dependent cellular
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cytotoxicity (ADCC), as compared to CD56dim HD- and PB-
NK cells (Figure 1). Moreover, the CD56dim PF-NK cell subset
showed a trend of increment in CD69 expression, thus indicating
that activated NK cells represented a large fraction of PF-NK cells
(Figure 1).
We also observed that the expression of CXCR4 was strongly
downregulated in PB-NK cells as compared to autologous PF-
NK cells as well as to HD-NK cells, suggesting a possible role
of this chemokine receptor in the recruitment of CD56dim NK
cells from the periphery to the tumor microenvironment. In
this context, we analyzed PF and plasma from matched patients
for the presence of up to 50 soluble factors using a Multiplex
Assay, in order to identify mediators potentially involved in
the shaping of the phenotypic/functional characteristics of PF-
NK cells (Table 1). This analysis revealed that PF is generally
enriched with the SDF-1alpha chemokine (the ligand for the
CXCR4 receptor) as compared to plasma derived from the same
patients. In some cases, this increase was >70%.
Phenotypic Comparison Between PB- and
PF-NK Cells Derived From Low-Grade or
High-Grade PC Patients
To understand if the differences between PB- and PF-NK cells
were features common to all patients or were dependent on
the tumor grade, we divided the patients into two groups: one
characterized by a low-grade disease (which included the well-
differentiated mesothelioma and the low-grade pseudomyxoma)
and the other characterized by high-grade disease (which
included peritoneal metastasis of primary colon or ovarian
carcinomas). By comparing the PB- and PF-NK cells of low-
grade PC patients, many differences highlighted in Figure 1 were
confirmed and even more evident. In particular, we observed
that the low-grade PC microenvironment was enriched with
more immature NK cells, characterized by lower expression
of CD16, KIR, LIR-1, and CD57 and higher expression of
NKG2A, as compared to autologous PB (Figures 2A,C and
Supplementary Figures 1, 2). In this regard, it is important to
consider that a CD16 downregulation was previously described
also on PF-NK cells from ovarian cancer patients, mainly due to
soluble factors, including IL-18 and TGF-beta (34, 35), present
in this compartment. In addition, a distinct CD56dim NK cell
subset, characterized by lower expression of CD16 and KIR and
undetectable levels of CD57, was described by different research
groups in different pathological conditions (39–41). Moreover,
the CD56dimCD16dim NK cell subset expressed higher levels of
CXCR4 (39).
In our case, the CD56dim PF-NK cell subset of low-
grade patients is characterized by the same features of
the subset previously described, including higher levels
of CXCR4 as compared to autologous PB (Figure 2 and
Supplementary Figures 1, 2).
On the other hand, no significant differences were detectable
between PB- and PF-NK cells from high-grade PC patients
(Figures 2B,C and Supplementary Figures 1, 2).
Comparison of PF-NK Cells Derived From
Low-Grade and High-Grade PC Patients
To fully understand if, in low-grade and high-grade PC
microenvironment, distinct features characterize NK cells, we
performed further analyses comparing PF-NK cells derived from
low-grade or high-grade PC.
Interestingly, in the PF of low-grade PC patients a large
fraction of CD56dim NK cells showed features of immature
NK cells, characterized by the NKG2A+KIR-CD57-CD16dim
phenotype, whereas the percentage of CD56dim NK cells
expressing KIR (Figures 3A,B) and LIR-1 (Figure 3A) was
increased in the PF of high-grade PC patients. In addition,
PF of low-grade PC patients contained a substantially higher
percentage of CD56bright NK cells than PF of high-grade PC
patients (average score: 48 vs. 27%).
By using the t-SNE algorithm, we observed that the co-
expression pattern of markers on NK cells generated specific
clusters associated with selected NK cell receptors (CD16,
NKG2A, and KIR), in the PF-NK cells of low-grade and high-
grade PC patients (Figure 3C). Furthermore, this approach
allowed to better visualize the different distribution of these NK
cell receptors in the PF-NK cells of these two groups of patients.
Moreover, an impaired expression of some activating NK
receptors, primarily NKp30 and DNAM-1, was shown on the
PF-NK cells from low-grade PC patients (Figure 3A). Previous
studies demonstrated that the defective expression and function
of activating NK cell receptors, including NKp30 and/or DNAM-
1, may be induced by the chronic engagement of these receptors
by their ligands in soluble form or expressed on tumor cells. In
this context, it is important to consider that CD45neg primary
cell lines derived from PF expressed some activating NK receptor
ligands including PVR and Nectin-2 (DNAM-1 ligands) (35),
and B7-H6 (NKp30 ligand) (34), although, in some of the
cases analyzed, this last molecule was only detectable in the
cytoplasm and not at the cell surface (Supplementary Figure 3).
In addition, PF microenvironment of low-grade PC patients
contained a much higher concentration of TGF-beta1 (an
increment over 80%) as compared to high-grade PC patients.
Considering that TGF-beta1 is known to induce down-regulation
of some activating NK cell receptors, including NKp30 (42), it is
likely that the downmodulation of NKp30 observed in low-grade
PC patients may be the result of the combined action of soluble
B7-H6 (sB7-H6) and TGF-beta1. Further analysis indicated that a
relationship between the level of NKp30 downmodulation on PF-
NK cells and the concentration of TGF-beta1 and sB7-H6 in the
PF could be established. More specifically, low-grade PC patients
displaying an important decrease in the expression of NKp30
exhibited also a high concentration of TGF-beta1 and sB7-H6
in the PF. On the other hand, high-grade patients displaying
higher levels of surface NKp30 on PF-NK were characterized
by very low concentration of TGF-beta1 and sB7-H6 in the
PF (Figures 4A,B).
Notably, TGF-beta1 could also be involved in the CD16
impairment (43, 44) detected in the PF-NK of low-grade
PC patients and in the induction of NKG2A expression, as
previously described in other tumor types (45, 46). Indeed, it
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FIGURE 2 | Comparison between PB- and PF-NK cells derived from low-grade and high-grade PC patients. Cytofluorimetric analysis of the expression of a panel of
cell surface markers on HD-NK ( bars) (n = 6), PB-NK of low-grade PC patients ( bars) (n = 5: Pt. 1, Pt. 6, Pt. 7, Pt. 8, Pt. 9) and PF-NK of low-grade PC patients
( bars) (n = 3: Pt. 1, Pt. 6, Pt. 8) (A). Cytofluorimetric analysis of the expression of a panel of cell surface markers on HD-NK ( bars) (n = 6), PB-NK of high-grade
PC patients ( bars) (n = 3: Pt. 2, Pt. 3, Pt. 4) and PF-NK of high-grade PC patients ( bars) (n = 3: Pt. 2, Pt. 3, Pt. 4) (B). Cells are gated on CD56dim NK cells. In
order to compare the expression of the three groups simultaneously (i.e., HD-NK, PB-NK, and PF-NK), we computed the Krustall rank sum tests for each cell surface
marker analyzed. *P < 0.05. (A,B) Dot plots derived from a representative healthy donor (HD-NK), a representative low-grade PC patient (PB-NK/PF-NK) and a
representative high-grade PC patient (PB-NK/PF-NK) are shown. Percentages of positive NK cells (gated on CD56dim subset as indicated by the dotted line) for the
indicated receptors are reported in the upper right quadrant of each dot plot (C).
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TABLE 1 | Soluble factors detected in plasma and peritoneal fluid (PF) of low-grade and high-grade PC patients compared with soluble factors detected in healthy donors (HD) plasma.
Patient Sample VEGF TRAIL TNF-b TNF-a SDF-1a SCGF-b SCF RANTES PDGF-bb MIP-1b MIP-1a MIG MIF MCP-3 MCP-1 (MCAF) M-CSF
HD 1 Plasma 10.28 160.055 460.8 88.565 695.965 202488.01 32.35 ND 20667.39 258.245 1.96 2364.995 1895.435 0.22 11.435 30.97
HD 2 Plasma 199.075 138.935 396.9 111.785 789.445 124500.015 52.735 ND 23018.27 280.365 1.17 339.63 2471.425 0 24.26 58.335
Pt. 1 Plasma 173.225 49.87 233.2 20.44 351.98 38700.6 6.91 2152.38 175.59 131.345 0.865 476.08 25.89 0 29.38 6.29
Pt. 2 Plasma 26.26 27.05 85.2375 2.855 113.3075 22372.235 7.2675 1001.33 52.9575 59.7825 1.01 240.6425 138.35 0.11 51.6375 1.5825
Pt. 3 Plasma 0 11.875 38.81 0.94 24.585 116900.705 7.74 296.505 84.65 59.86 1.91 822.31 194.72 1.82 580.605 13.38
Pt. 4 Plasma 182.73 101.465 289.27 29.755 471.935 61759.515 16.055 2810.5 217.905 159.76 0.85 669.645 1420.815 0 114.295 5.475
Pt. 6 Plasma 0 132.93 246.78 56.61 606.365 79799.94 69.865 6180.09 304.16 144.87 3.085 4405.87 853.22 2.415 137.95 48.335
Pt. 7 Plasma 149.805 119.5 280.45 24.905 461.575 42892.27 23.43 6357.5 748.89 172.025 0.96 665.3 940.995 0.42 96.775 19.64
Pt. 8 Plasma 0 107.385 285.975 36.42 534.265 83015.745 26.33 11953.38 403.195 169.9 1.315 418.4 1305.49 0 68.695 0
Pt. 1 PF 243.795 32.4 45.635 40.81 1312.535 204341.7 51.31 309.675 94.265 60.275 6.34 1723.75 361.75 3.515 66.62 21.815
Pt. 2 PF 0 20.395 36.855 9.275 156.17 2373.91 5.37 327.12 39.58 28.25 1.235 85.095 1631.79 0 19.845 0.88
Pt. 6 PF 206.17 161.195 70.05 272.79 1939.845 180303.03 71.175 75.25 170.66 244.47 133.45 10117.56 17280.6 454.985 ND 41.475
Pt. 8 PF 131.145 25.785 39.775 57.16 1165.935 76851.885 38.05 171.555 56.12 88.06 12.32 488.88 5486.46 6.9 145.96 4.87
Patient Sample LIF IP-10 IL-9 IL-8 IL-7 IL-6 IL-5 IL-4 IL-3 IL-2Ra IL-2 IL-1ra IL-1b IL-1a IL-18 IL-17
HD 1 Plasma 4.23 1918.885 421.4 233.155 51.89 2.21 0 4.74 0 118.125 0 426.365 2.12 9.32 101.44 4.71
HD 2 Plasma 3.14 2095.385 352.525 97.61 146.895 6.38 0 9.055 0 69.145 0 1751.08 6.075 8.505 100.32 14.895
Pt. 1 Plasma 13.995 400.91 223.48 4.66 12.615 0.955 0 2.265 0 43 0 0 0.645 5.435 9.695 0
Pt. 2 Plasma 5.5275 186.65 88.1125 7.0725 2.26 0.53 0 1.405 0 23.8325 0 33.89 0.635 2.4325 7.44 0
Pt. 3 Plasma 6.375 0 34.63 60.44 0 277.05 0 1.025 0 60.31 0 259.99 0.71 4.865 18.775 0
Pt. 4 Plasma 0 788.26 266.22 50.34 0.605 21.285 0 4.47 0 45.6 0 375.455 1.11 0 13.435 0
Pt. 6 Plasma 0.58 1033.445 222.565 19.42 0 19.555 7.855 2.79 0 539.595 0 127.415 0.825 8.28 98.205 1.065
Pt. 7 Plasma 0 93.41 296.04 33.58 36.3 25.775 8.875 1.635 0 51.59 0 31.2 0.8 4.865 14.865 0
Pt. 8 Plasma 110.9 440.87 262.735 14.55 9.07 0.845 0 1.205 0 81.025 0 116.585 0.075 1.035 18.46 0
Pt. 1 PF 30.495 5694.53 42.955 118.26 7.73 657.55 9.18 2.405 0 509.645 1.24 39.36 0.835 9.725 14.21 3.96
Pt. 2 PF 6.17 221.97 42.48 6.35 2.645 1.87 0 0.8 0 8.215 0 51.89 0.295 1.215 2.065 1.44
Pt. 6 PF 117.065 #DIV/0! 74.45 9170.92 15.59 5494.13 55.24 11.35 1.17 1067.33 6.665 4488.69 4.62 27.755 73.68 22.25
Pt. 8 PF 60.945 1760.75 41.615 395.75 15.505 649.12 11.445 3.63 0 252.995 0.105 166.42 0.72 3.72 16.01 6.125
Patient Sample IL-16 IL-15 IL-13 IL-12p40 IL-12(p70) IL-10 IFN-g IFN-a2 HGF GROa GM-CSF G-CSF FGF b Eotaxin CTACK b-NGF
HD 1 Plasma 327.035 6.97 0 33.205 0.07 1.465 0 3.02 2074.565 526.38 0 48.84 8.225 40.745 1716.99 1.345
HD 2 Plasma 908.425 15.375 0 30.5 0 1.465 40.335 2.33 2042.815 952.65 5.325 113.035 13.66 405.53 955.815 3.4
Pt. 1 Plasma 29.68 12.625 0 2.65 0.07 0.02 0 0 238.33 299.14 0 50.745 0.825 83.525 989.48 1.345
Pt. 2 Plasma 34.69 0 0 3.0775 0 1.245 0 0 180.8 123.745 0 33.79 1.2375 31.3125 465.12 0
Pt. 3 Plasma 6.45 0 0 12.35 0.07 0 125.35 4.74 2187.025 0 0 54.435 2.475 21.865 79.455 0
Pt. 4 Plasma 55.1 0 0 0 0.88 0 8.825 0 424.265 317.125 0 95.745 2.475 72.93 1791.72 0
Pt. 6 Plasma 171.58 329.125 0 3.57 0.07 0 91.275 1.585 902.7 389.41 5.705 114.815 4.265 133.575 1452.625 5.895
Pt. 7 Plasma 81.985 194.27 0 11.07 2.985 273.685 0 0 443.885 443.59 4.31 65.075 3.645 129.18 755.355 9.065
Pt. 8 Plasma 84.785 0 0 0 0 1.465 6.32 0.955 612.41 290.065 0 59.03 0.825 134.885 924.92 0
Pt. 1 PF 219.89 3.39 0.145 60.135 0.59 22.765 78.11 3.7 3570.565 125.21 0 145.975 5.49 15.27 1370.125 5.345
Pt. 2 PF 62.965 0 0 4.51 0.02 0.54 0 1.495 148.58 54.315 0 23.845 41.905 8.92 115.165 0.175
Pt. 6 PF 867.895 48.965 3.055 93.975 1.715 28.525 441.335 22.48 2151.51 622.24 3.625 1747.37 13.415 59.71 1081.29 7.54
Pt. 8 PF 224.455 0 1.07 51.775 0.22 69.325 54.42 5.105 2120.91 195.885 0.315 273.885 15.695 58.47 1013.39 6.225
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FIGURE 3 | Comparison of PF-NK cells derived from low-grade and high-grade PC patients. Cytofluorimetric analysis of the expression of a panel of cell surface
markers on PF-NK derived from low-grade PC patients (low-grade PF-NK) ( bars) (n = 3:Pt. 1, Pt. 6, Pt. 8) and PF-NK derived from high-grade PC patients
(high-grade PF-NK) ( bars) (n = 3: Pt. 2, Pt. 3, Pt. 4). The power (pwr) and Cohen’s distance (d), calculated with the Power Analysis for Two-group Independent
sample t-test, of the pair are indicated when significant (power ≥ 0,8) (A). Distribution of KIR and NKG2A receptors on gated CD56dim NK cells of low-grade PC
patients and high-grade PC patients. A representative donor is shown for each group of patients (B). t-SNE clusterization of CD56dim PF-NK cells derived from a
representative low-grade PC patient (Pt. 6) and a representative high-grade PC patient (Pt. 4). The color scale represents the different distribution of CD16, NKG2A,
and KIR receptors evaluated through the variation of Geo-mean (C). Heatmap showing the clustering of low-grade (Pt. 1, Pt. 6, Pt. 8) and high-grade (Pt. 2, Pt. 3, Pt.
4) PC patients based on the differential expression of the indicated NK cell receptors on gated CD56dim NK cells. The color scale goes from blue (low relative
expression) to red (high relative expression) and it is based on the variation of each single receptor through the six patients (D).
was possible to observe a relationship between the level of CD16
downmodulation on PF-NK cells and TGF-beta1 concentration
in the PF (Figure 4A).
Thus, the impaired expression of both activating and
inhibitory receptors on PF-NK cells from low-grade PC patients
induced by tumor cells and/or soluble factors present in the PF
microenvironment may contribute to the development of escape
mechanisms from immune surveillance.
Regarding the PF-NK cells from high-grade PC patients,
we observed a trend of increment in the expression of the
PD-1 inhibitory checkpoint. The fact that this difference is
not clearly significant may depend on the small number
of PC patient samples analyzed, due to the rarity of this
disease. Considering that the expression of this inhibitory
receptor on NK cells can compromise their anti-tumor activity,
and that PF-derived primary cell lines express both PD-
L1 and PD-L2 (Supplementary Figure 3), the increased PD-1
expression may play a role in inducing NK cell impairment in
tumor control.
To support our findings regarding the significant differences
between PF-NK cells derived from low-grade and high-
grade PC patients, we perform hierarchical clustering in
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FIGURE 4 | Relationship between NKp30 or CD16 expression on PF-NK cells and soluble factor’s concentration in the PF of low-grade and high-grade PC patients.
Relationship between NKp30 or CD16 receptor downregulation on PF-NK cells and TGF-beta1 concentration in the PF of low-grade PC patients ( dots, n = 3: Pt. 1,
Pt. 6, Pt. 8) or high-grade PC patients ( dots, n = 2: Pt. 2, Pt.3). The linear regression line is shown (NKp30 vs. TGF-beta1: R = 0.52 and p = 0.17; CD16 vs.
TGF-beta1: R = 0.68 and p = 0.09) (A). Histograms showing the expression of NKp30 on PF-NK cells of a representative low-grade PC patient (Pt. 6) and a
representative high-grade PC patient (Pt. 2) and TGF-beta1/sB7-H6 concentration in PF of the same patients (B).
order to verify the presence of particular patterns in our
data. In Figure 3D, the two-color heatmap plots show
the unsupervised hierarchical clustering of NK samples
derived from PF of PC patients. This analysis clearly
separates low-grade from high-grade samples, based on the
different expression of a small group of classical NK cell
molecules, including the activating and inhibitory receptors
appointed above.
Thus, the low-grade or high-grade PC tumor
microenvironment may differently contribute to the tumor
escape from immune surveillance, by inducing different shaping
in the tumor-associated NK cell receptors repertoire (e.g.,
down-regulation of activating receptors vs. up-regulation of
inhibitory ones).
Functional Comparison Between PB- and
PF-NK Cells Derived From Low-Grade or
High-Grade PC Patients
To support our results regarding the impaired expression of some
activating NK receptors (primarily NKp30) on the PF-NK cells
from low-grade PC patients, degranulation assays against K562, a
HLA-I negative cell line previously shown to express B7-H6, were
performed in the absence or in the presence of the anti-NKp30
blocking mAb. The results were compared with those obtained
using HD-NK cells.
As shown in Figure 5, PB-NK cells derived from a
representative low-grade PC patient or a representative high-
grade PC patient as well as HD-NK cells displayed ability
to degranulate following exposure to K562. These functional
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FIGURE 5 | Degranulation assay of PB- and PF-NK cells derived from
low-grade and high-grade PC patients. Degranulation assay (CD107a
expression) of PB- and PF-NK cells from a representative low-grade PC
patient (Pt. 6), a representative high-grade PC patient (Pt. 3) and a
representative HD stimulated by K562 tumor target cells, in the absence or in
the presence of anti-NKp30 mAb. Percentages of CD107a+ NK cells are
reported in the upper right quadrant of each dot plot.
activities were inhibited in the presence of anti-NKp30 mAb,
capable of disrupting the NKp30/B7-H6 interaction.
On the contrary, under the same conditions, PF-NK cells
derived from both types of PC patients were characterized by
substantial differences in terms of degranulation. In particular, as
expected, the degranulation of PF-NK cells derived from the low-
grade PC patient (characterized by a compromised expression
of NKp30) was lower than that of HD-NK and autologous
PB-NK cells (expressing normal levels of NKp30). Again the
degranulation was partially inhibited in the presence of anti-
NKp30 mAb.
On the other hand, unexpectedly, the degranulation activity of
PF-NK cells derived from the high-grade PC patient was deeply
impaired, either in the absence or in the presence of anti-NKp30
(Figure 5), despite the normal expression of NKp30. The same
result was obtained by using PD-L+ tumor cell lines (including
OVCAR5), either in the absence or in the presence of anti-PD-1
mAb (not shown). These data suggest that PF-NK cells derived
from the high-grade PC patient present additional impairments
(other than PD-1-mediated block) still to be defined. In this
context, it is important to consider that in the PF the ratio
between NK cells and tumor cells is clearly unbalanced toward
tumor cells, probably due to a defective migration of NK cells
within this compartment. This event can decrease the chances
that NK cells can efficiently meet and kill cancer cells even in in
vitro experiments.
Impact of a CRS/HIPEC Successful
Treatment on NK Cell Compartment: A
Case Presentation
In order to acquire insights on the effect of the CRS/HIPEC
therapy, we characterized PB- and PF-NK cells derived from
Patient 1, affected by pseudomyxoma peritonei, before (time
0), and at different time points (time 1 and time 2) after
therapy. At time 0, PF-NK cells, but not PB-NK cells, showed a
highly compromised phenotype in terms of anti-tumor potential.
In fact, PF-NK cells were characterized by a strong down-
regulation of the main NK cell-activating receptors, in particular
NKp46, DNAM-1, NKp30, and CD16 (Figure 6). In addition,
differently from autologous PB, a higher fraction of PF-NK
cells was NKG2A+, whereas only a minor cell subset expressed
KIR. Notably, starting from time 1, the percentages and surface
density of NKp46 and NKp30 were greatly increased, whereas
those of DNAM-1 were only slightly increased. At time 2, the
expression of all activating receptors, including CD16, was almost
completely recovered and comparable to that of the patient’s
PB (and to a HD-NK, see Figures 1, 2A,C). Furthermore, a
re-balancing in the distribution of KIR and NKG2A could be
observed. In fact, if at time 0 almost all PF-NK cells were
NKG2A+ KIR-, at time 2 the percentages of KIR+ NK cells
were increased by 60% and the percentages of NKG2A+NK cells
were decreased by 25%. This result means that the CRS/HIPEC
therapy in PC tumor patients can induce phenotypic changes
on NK cells, thus reverting tumor-induced NK cell suppression,
although the molecular mechanisms of this effect still need to be
fully clarified. Importantly, the prognosis of patient 1 was very
favorable. To date 4 years after treatment, this patient is in good
health, with no evidence of disease recurrence.
DISCUSSION
Peritoneal carcinomatosis (PC) is the site of histologically
heterogeneous rare primitive diseases (including pseudomixoma
peritonei and mesothelioma) and one of the problematic
sites of metastases for abdominal malignancies, including
gastrointestinal, and ovarian cancers (1–4). Its presentation is
usually associated with a significantly reduced quality of life and
a very poor prognosis. To date, PC remains among the most
common causes of death from abdominal cancers.
Intraperitoneal chemotherapy with surgical debulking
is associated with higher survival rates than systemic
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FIGURE 6 | Reversion of the altered NK cell phenotype in a low-grade PC patient after the CRS/HIPEC treatment. Dot plots illustrating the expression of different NK
cell receptors on PB-NK and PF-NK derived from a low-grade PC patient (Pt. 1), before treatment (time 0), and 48 h (time 1), or 7 days (time 2) after CRS/HIPEC
treatment. Percentages of NK cells (gated on CD56dim subset as indicated by the dotted line) positive for the indicated receptors are reported in the upper right
quadrant of each dot plot.
chemotherapy, but results are still disappointing, and treatment
is rarely curative (3). Several independent groups have reported
that immune modulating agents can provide a significant
therapeutic benefit in preclinical models of PC (47–50). These
promising results suggest that strategies based on increasing the
anti-tumor immune response within the peritoneal cavity should
be pursued in PC treatment.
NK cells are a major component of the anti-tumor
immune response and are involved in controlling tumor
progression and metastases. However, tumors have evolved
mechanisms of immunoevasion, including production of pro-
tumoral/immunosuppressive cytokines, expression of ligands for
inhibitory receptors, or loss of ligands for activating receptors
in order to escape from the NK cell-mediated attack. Here,
we show that in PC patients, tumor-associated NK cells
are characterized by phenotypic and functional dysfunctions.
Interestingly, the NK cell impairment is different between
patients with low-grade or high-grade PC. In particular, we
observed a large fraction of immature NKG2A+ CD57- NK
cells displaying a strong downregulation of the main activating
NK cell receptors (such as NKp30, DNAM-1, and CD16) in
low-grade PC patients vs. a most mature KIR+ CD57+ NK
cell fraction showing an up-regulation/induction of the immune
checkpoint PD-1 in high-grade PC patients. In both cases,
PF-NK cells displayed functional defects, however, while in
low-grade PC patients these defects reflected the compromised
phenotype, in the high-grade PC patients PF-NK cells showed
much more important defects that only partially reflected the
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compromised phenotype detected. This suggests that further
impairments, still to be highlighted, exist at the level of this NK
cell population.
Thus, based on the tumor grade, PC microenvironment may
be characterized by structural and functional reorganization
by inducing different tumor escape mechanisms from
immune surveillance. In this context, it has been previously
demonstrated that metastatic PC from primary colorectal
cancer (pCRC) is characterized by modification in tumor
microenvironment and immune cell reaction. These changes
include senescence in PC tumor cells, and enhancement of
pro-tumoral soluble factors, including VEGF-A and TGF-
beta, that promote neovascularization in metastatic niche and
tumor growth/invasion/metastasis formation, respectively. The
authors also found high amount of the NK cell-regulating
cytokine IL15 and a significantly increased numbers of mature
(CD57+) NK cells expressing CD107a on the surface and
releasing high levels of IFN-gamma and TNF (47). Another
research group has recently demonstrated that recruitment of
cytotoxic, IFN-gamma-secreting, NK cells is associated with
reduced tumor burden, and improved survival in a colon
cancer model of PC (48). All these data suggest that NK cells
can play a crucial immunosurveillance role in PC. Thus, the
balance between anti-tumor and pro-tumor effects can deeply
influence the anti-tumor activity of these immune cells and the
metastasis formation.
Understanding the mechanisms by which PC tumor
microenvironment works in inducing immune cells suppression
is a complex issue, also considering that these types of tumors
are uncommon and histologically heterogeneous, ranging from
benign to highly malignant.
By analyzing the phenotype of NK cells derived from
PF of low-grade and high-grade PC patients, we found that
the PF compartment of low-grade disease is enriched in
most immature NKG2A+KIR-CD57-CD16dim NK cells. A
NK cell subset characterized by a similar phenotype and
endowed with multifunctional activity (including potent killer
and IFN-gamma producing capacity) was found in the bone
marrow both of healthy children and of pediatric leukemic
patients and it has been suggested that this NK cell subset
can represent an intermediate differentiation stage between
CD56brightCD16neg/dim and CD56dimCD16bright NK cells
(39). Interestingly, these immature PF-NK cells are characterized
by a strong downregulation of the main activating NK cell
receptors (primarily NKp30 and DNAM-1) that may be a
consequence of their engagement by specific ligands expressed
on tumor cell surface or present in soluble form together with
immunomodulatory soluble factors in the PF. In this context,
it has been previously demonstrated that chronic receptor-
ligand interactions may dampen the surface expression of some
activating NK receptors, thus affecting the ability of NK cells
to kill tumor cells expressing ligands for those receptors. In
particular, a soluble form of B7-H6 (sB7-H6), the main NKp30
ligand, was found in the PF-microenvironment of ovarian cancer
patients (34). A high amount of sB7-H6 is correlated with
a greater downmodulation of NKp30. These NK cells display
impaired IFN-gamma production and cytolytic function, thereby
showing poor NK cell-mediated elimination of B7-H6+ ovarian
cancer cells (34). Moreover, the activating NK cell receptor
DNAM-1 can also be downmodulated by the chronic exposure to
the ligand expressed on the surface of ovarian tumor cells (35). In
addition, TGF-beta can also contribute to the downmodulation
of the NKp30 activating receptor (42). Consistent with these
observations, we detected the expression of ligands for NKp30
(B7-H6) and DNAM-1 (PVR, Nectin-2) on PF-derived tumor
cells and several soluble factors, including sB7-H6, and TGF-beta,
in the PF. These factors are certainly involved in the induction
of the compromised phenotype observed in the PF-NK cells of
low-grade PC patients.
With disease progression (high-grade PC tumors), we found
that expression of activating NK cell receptors (including
NKp30, DNAM-1, and CD16) was recovered, and the
expression of inhibitory receptors (such as KIRs, LIR-1,
and PD-1) increased together with the maturation state of
NK cells.
Thus, low-grade and high-grade PC tumors shape their
environment differently in order to evade NK cell anti-tumor
immunity. Along this line, PF-NK cells from both low-grade and
high-grade PC patients showed decreased NK cell degranulation
function. Importantly, this impairment was apparently more
pronounced in NK cells from high-grade PC patients, even
if, in this case, it is not clear which mechanisms lead to the
lack of NK cell degranulation capacity. Indeed, this defect
also occurs with respect to target cells (i.e., K562) that do
not express ligands for inhibitory receptors (i.e., HLA-I and
PD-Ls molecules) up-regulated on PF-NK cells, but express
ligands for activating receptors (e.g., B7-H6) that are normally
expressed on these cells. However, because the percentage
of NK cells was severely reduced in the PF of the high-
grade PC, the fact that PF-NK cells from high-grade PC
tumor were unable to fulfill their degranulation function is
not surprising considering their low proportion within the
tumor. Further investigations will be necessary to clarify
this aspect.
Thus, cancer cells and the tumor milieu can deeply
alter the functional composition of anti-tumor effector cells,
including cytotoxic NK cells. This consideration highlights
the importance of developing future therapies able to restore
NK cell cytotoxicity and limit/prevent tumor escape from
anti-tumor immunity.
Remarkably, we show that in a low-grade PC patient, with
no evidence of disease recurrence after 4 years after treatment,
CRS/HIPEC treatment could restore the NK cells impaired
phenotype, thus reverting tumor-induced NK cell suppression.
In this scenario, we can hypothesize that removal of the tumor
(CRS) combined with HIPEC procedure may improve survival
in low-grade PC patients by reducing the tumor factors involved
in immune cell suppression (37, 51).
On the other hand, since most high-grade PC remains
refractory or responds only partially to the CRS/HIPEC
treatment, new therapeutic approaches aimed at increasing
the effectiveness of the current therapy are necessary
(52, 53). For example, immunotherapeutic reagents capable
of blocking inhibitory receptors expressed by NK cells
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or strengthening the ADCC mechanism (mainly in high-
grade PC patients with normal CD16 expression) could be
associated to the CRS/HIPEC treatment in order to enhance the
anti-tumor response.
In summary, this study contributes toward identification of
possible markers of prognosis or candidates that may represent
possible targets in immunotherapeutic approaches aiming to
strengthen the anti-tumor activity of NK cells in PC tumors (15–
18, 54, 55), a disease that has not been adequately investigated yet
due to its rarity.
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